Influenza A viruses exhibit extreme diversity as exemplified by the multiple serotypes of the hemagglutinin (HA, H1-H18) and neuraminidase (NA, N1-N11) surface antigens. To date, only three of the possible 198 combinations found in avian and other animal reservoirs have been associated with human pandemics (H1N1, H2N2, H3N2). However, ever increasing anxiety about the potential for infections by infections of zoonotic origin have heightened concern about emergence of a human transmissible virus that could devastate the human population. The emergence of H5N1, H6N1, H7N7, H7N9, H9N2, and H10N8 viruses in the human population are constant reminders of this possibility. Influenza B viruses with its two distinct lineages further increase the health and economic burden of seasonal influenza worldwide. This proposal seeks to elucidate, at the structural level, key sites of vulnerability on influenza virus that can be utilized to develop therapeutics as well as improved vaccines. Antibody-mediated neutralization of influenza virus is a complex combinatorial problem for the human immune system as it is presented with diverse, highly variable and constantly evolving viruses. While neutralizing antibodies against human flu are traditionally regarded as being strain specific, recent advances have shown that much broader responses can be mounted that give valuable insights into conserved sites of vulnerability. We are therefore amassing compelling evidence that a sustained, cross- serotype response can be mounted against influenza and this vital information can now be harnessed for design of small molecules, peptides, and proteins to target these key sites of vulnerability, thereby blocking influenza infection. No effective drugs are currently available for preventing the entry of influenza virus. Thus, we will elucidate common features for recognition of sites of vulnerability of pandemic and emerging influenza viruses from crystal structures of diverse HAs with broadly neutralizing antibodies and sialosides that are mimics of the natural receptor. A combined biophysical, biochemical, and chemical approach employing state- of-the-art structural biology, glycan arrays, and chemical biology will be used to provide key insights into influenza virus neutralization that enable design of novel therapeutics to control and combat future influenza pandemics and seasonal epidemics.

Public Health Relevance

We will determine sites of vulnerability on influenza virus from structural studies of influenza hemagglutinin in complex with broadly neutralizing antibodies and sialoside receptors. Recurring themes of recognition will provide a platform for design of small molecules, peptides, and small proteins as potential therapeutics to prevent influenza virus infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56AI117675-01
Application #
9114253
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
Hauguel, Teresa M
Project Start
2015-08-01
Project End
2016-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
1
Fiscal Year
2015
Total Cost
$835,902
Indirect Cost
$394,793
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Kadam, Rameshwar U; Wilson, Ian A (2018) A small-molecule fragment that emulates binding of receptor and broadly neutralizing antibodies to influenza A hemagglutinin. Proc Natl Acad Sci U S A 115:4240-4245
Laursen, Nick S; Friesen, Robert H E; Zhu, Xueyong et al. (2018) Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science 362:598-602
de Vries, Robert P; Tzarum, Netanel; Peng, Wenjie et al. (2017) A single mutation in Taiwanese H6N1 influenza hemagglutinin switches binding to human-type receptors. EMBO Mol Med 9:1314-1325
Tzarum, Netanel; McBride, Ryan; Nycholat, Corwin M et al. (2017) Unique Structural Features of Influenza Virus H15 Hemagglutinin. J Virol 91:
Kadam, Rameshwar U; Juraszek, Jarek; Brandenburg, Boerries et al. (2017) Potent peptidic fusion inhibitors of influenza virus. Science 358:496-502
Wu, Nicholas C; Xie, Jia; Zheng, Tianqing et al. (2017) Diversity of Functionally Permissive Sequences in the Receptor-Binding Site of Influenza Hemagglutinin. Cell Host Microbe 22:247-248
Strauch, Eva-Maria; Bernard, Steffen M; La, David et al. (2017) Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site. Nat Biotechnol 35:667-671
Wu, Nicholas C; Zost, Seth J; Thompson, Andrew J et al. (2017) A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog 13:e1006682
Lang, Shanshan; Xie, Jia; Zhu, Xueyong et al. (2017) Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem. Cell Rep 20:2935-2943
Wu, Nicholas C; Grande, Geramie; Turner, Hannah L et al. (2017) In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity. Nat Commun 8:15371

Showing the most recent 10 out of 21 publications